SBC Medical Group (NASDAQ:SBC) reported a 13% year-over-year increase in second-quarter revenue, reaching $49 million, following structural reforms in 2025. Adjusted EBITDA rose 32% to $20 million, achieving an adjusted EBITDA margin of 41%. These results come despite the adverse effects of a weaker yen, as the company continues to expand its management services revenue.
As of June 30, SBC operated 287 locations, a net increase of 34 from the previous year, with customer visits totaling 6.92 million—up 10%. In aesthetic dermatology, first-half transaction value increased by 19%, while a new focus on non-aesthetic healthcare aims to shift the current 84% aesthetic service revenue composition. The company has $184 million in cash, prioritizing organic growth and disciplined M&A.
In addition, SBC is establishing a clinic in Thailand under a new “Powered by SBC” model and plans to open a longevity center in Japan by 2027. Strategic collaborations, like its partnership with OrangeTwist in the U.S., are intended to enhance service offerings and generate recurring revenue.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
